

# **Pain Assessment after Short Course versus Long Course Palliative Radiation of Painful Bony Metastasis**

Thesis

*Submitted for Partial Fulfilment of Master Degree in  
Clinical Oncology and Nuclear Medicine*

By

***Abdelfattah Rashad Abdelfattah Elmasry***  
*M.B.B.C.H.*

Under supervision of

**Prof. Dr. Khaled Abdelkarim Mohamed**

*Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine – Ain Shams University*

**Dr. Dalia Abd El-Ghany El-Khodary**

*Assistant Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine – Ain Shams University*

**Dr. Ahmed Mostafa Mohamed**

*Lecturer of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine – Ain Shams University*

**Faculty of Medicine - Ain Shams University**

**2018**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

لَوْ قُلَّ رَبِّ  
زِدْنِي عِلْمًا

سورة طه  
الآية (١١٤)

صَدَقَ اللَّهُ الْعَظِيمُ

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Khaled Abdelkarim Mohamed**, Professor of Clinical Oncology and Nuclear Medicine - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Dalia Abd El-Ghany El-Khodary**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Ahmed Mostafa Mohamed**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

*Abdelfattah Rashad Abdelfattah Elmasry*

# *List of Contents*

Title	Page No.
List of Tables .....	i
List of Algorithms .....	iii
List of Figures .....	iv
List of Abbreviations .....	v
Introduction .....	1
Aim of the Work.....	3
Review of Literature	
Chapter (1): Bone Metastases .....	4
A. Incidence and Distribution of Bone Metastases.....	4
B. Normal bone physiology and turnover .....	6
C. Types of bone metastasis .....	6
D. Pathophysiology of bone metastases.....	8
E. Clinical aspects OF BONE METASTASES.....	12
F. Laboratory Studies .....	27
G. Imaging in Bone Metastases .....	28
Chapter (2): Bone Metastases Management Overview .....	37
A. Painful Bone Metastases Management Overview.....	37
1. Introduction to treatment concepts.....	37
2. Approach for Pain Management:.....	39
3. Approved therapeutic agents.....	40
B. Management of Other Skeletal Related Adverse Events.....	68
Spinal cord compression (including cauda equina syndrome).....	68
Symptomatic malignancy-related hypercalcemia.....	73

## *List of Contents (Cont..)*

Title	Page No.
Chapter (3): The Role of Radiation Therapy in Bone Metastases Management.....	74
A. Indications and aims of radiation therapy .....	75
B. Effects of radiation therapy on bone metastases .....	77
C. Fractionation schedules .....	78
D. Response to radiation therapy .....	84
E. Toxicity of radiation therapy .....	85
F. Radiation therapy techniques .....	88
G. Re-irradiation .....	93
H. Future perspectives .....	96
Patients and Methods .....	98
Results .....	104
Discussion .....	126
Summary and Recommendations .....	137
References .....	138
Arabic Summary	

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Main clinical circumstances that may influence the selection of the fractionation schemes .....	78
<b>Table (2):</b>	Comparison of clinic-pathological data within both groups .....	105
<b>Table (3):</b>	Response rate within both groups .....	107
<b>Table (4):</b>	Comparison of mean pain score within both groups through determined pain assessment intervals.....	108
<b>Table (5):</b>	Comparison of mean pain score through determined pain assessment intervals in patients receiving 300 cGy x 10 fractions .....	109
<b>Table (6):</b>	Comparison of mean pain score through determined pain assessment intervals in patients receiving 400 cGy x 5 fractions .....	110
<b>Table (7):</b>	Pain response regarding baseline pain severity.....	111
<b>Table (8):</b>	Use of narcotics before & after 3 months of radiotherapy .....	112
<b>Table (9):</b>	Comparison of pain response between both genders in patients received 400 cGy x 5 fractions.....	114
<b>Table (10):</b>	Comparison of pain response between both genders patients received 300 cGy x 10 fractions .....	115
<b>Table (11):</b>	Comparison of pain response between both types of malignancies in patients who received 400 cGy x 5 fractions .....	116
<b>Table (12):</b>	Comparison of pain response between both types of malignancies in patients who received 300 cGy x 10 fractions .....	117

## *List of Tables (cont...)*

Table No.	Title	Page No.
<b>Table (13):</b>	Comparison of pain response between both fractionation arms in 6 cases with prostate cancer .....	118
<b>Table (14):</b>	Comparison of pain response between both fractionation arms in 22 cases with breast cancer .....	119
<b>Table (15):</b>	Comparison of pain response according to fractionation schedule in 16 cases with peripherally located bone metastases.....	120
<b>Table (16):</b>	Comparison of pain response according to fractionation schedule in 34 cases with centrally located bone metastases. ....	121
<b>Table (17):</b>	Comparison of pain response according to fractionation schedule in 38 cases with absent extraosseous component. ....	122
<b>Table (18):</b>	Comparison of pain response according to fractionation schedule in 12 cases associated with extraosseous component.....	123
<b>Table (19):</b>	Comparison of pain response according to fractionation schedule in patients 35 patients younger than 60 years old .....	124
<b>Table (20):</b>	Comparison of pain response according to fractionation schedule in 15 patients 60 years old or older .....	125

## *List of Algorithms*

Algorithm No.	Title	Page No.
<b>Algorithm (1):</b>	Treatment of cancer pain .....	41
<b>Algorithm (2):</b>	Treatment of pain due to bone metastases .....	42



## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	The development of bone metastases can be considered in several stages: colonization, quiescence, progression either locally leading to overt metastasis in bone or dissemination to another site.....	10
<b>Figure (2):</b>	Showing the data collection tool used.....	100
<b>Figure (3):</b>	Percentage of different cancer types within study population.....	106
<b>Figure (4):</b>	Main pain score in both treatment arms through determined assessment intervals .....	110
<b>Figure (5):</b>	Percentage of narcotic use before and after each fractionation regimen .....	112

## *List of Abbreviations*

<b>Abb.</b>	<b>Full term</b>
<b>3-DCRT</b> .....	<i>Three-dimensional conformal radiation therapy</i>
<b>ASTRO</b> .....	<i>American Society for Radiation Oncology</i>
<b>ATP</b> .....	<i>Adenosine triphosphate</i>
<b>BC</b> .....	<i>Breast cancer</i>
<b>BMP</b> .....	<i>Bone morphogenic proteins</i>
<b>BPI</b> .....	<i>Brief Pain Inventory</i>
<b>BTP</b> .....	<i>Breakthrough pain</i>
<b>CA15-3</b> .....	<i>Carcinoma Antigen 15-3</i>
<b>Cbfa1</b> .....	<i>Core binding factor alpha1</i>
<b>CNS</b> .....	<i>Central nervous system</i>
<b>COX-2</b> .....	<i>Cyclo-oxygenase-2</i>
<b>CT</b> .....	<i>Computed tomography</i>
<b>CXCR4</b> .....	<i>C-X-C chemokine receptor type 4</i>
<b>DNA</b> .....	<i>Deoxyribonucleic acid</i>
<b>DW-MRI</b> .....	<i>Diffusion-weighted magnetic resonance imaging</i>
<b>EBRT</b> .....	<i>External beam radiotherapy</i>
<b>EDTMP</b> .....	<i>Ethylenediaminetetramethylene phosphate</i>
<b>EORTC QLQ</b> ...	<i>European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire</i>
<b>FDA</b> .....	<i>Food and Drug Administration</i>
<b>FDG</b> .....	<i>Fludeoxyglucose</i>
<b>HBI</b> .....	<i>Hemi-body irradiation</i>
<b>HIFU</b> .....	<i>High intensity focused ultrasound</i>
<b>IASP</b> .....	<i>International Association for the Study of Pain</i>
<b>IP</b> .....	<i>Investigational Product</i>
<b>IT</b> .....	<i>Intra-thecal</i>
<b>ITDD</b> .....	<i>Intra-thecal drug delivery</i>
<b>IV</b> .....	<i>Intravenous</i>

## *List of Abbreviations (cont...)*

<b>Abb.</b>	<b>Full term</b>
<b>MM</b> .....	<i>Multiple myeloma</i>
<b>MRI</b> .....	<i>Magnetic resonance imaging</i>
<b>MSCC</b> .....	<i>Metastatic spinal cord compression</i>
<b>mTOR</b> .....	<i>Mammalian target of rapamycin</i>
<b>NCCN</b> .....	<i>National Comprehensive Cancer Network</i>
<b>NMDA</b> .....	<i>N-methyl-D-aspartate</i>
<b>NNT</b> .....	<i>Number needed to treat</i>
<b>NP</b> .....	<i>Neuropathic pain</i>
<b>NSAIDS</b> .....	<i>Nonsteroidal anti-inflammatory drugs</i>
<b>NTx</b> .....	<i>N-telopeptide</i>
<b>OMED</b> .....	<i>Daily oral morphine equivalent</i>
<b>ORT</b> .....	<i>Opioid Risk Tool</i>
<b>PET</b> .....	<i>Positron-emission tomography</i>
<b>PROMIS</b> .....	<i>Patient Reported Outcomes Measurement Information System</i>
<b>PSA</b> .....	<i>Prostate-specific antigen</i>
<b>PTH</b> .....	<i>Parathyroid hormone</i>
<b>PTHrP</b> .....	<i>Parathyroid hormone related peptide</i>
<b>QOL</b> .....	<i>Quality of life</i>
<b>RANK</b> .....	<i>Receptor activator of NF-kappa B</i>
<b>RANKL</b> .....	<i>Receptor activator of NF-kappa B ligand</i>
<b>RCT</b> .....	<i>Randomized controlled trial</i>
<b>RFA</b> .....	<i>Radiofrequency ablation</i>
<b>RR</b> .....	<i>Response Rate</i>
<b>RT</b> .....	<i>Radiotherapy</i>
<b>S.C</b> .....	<i>Subcutaneous</i>
<b>SBRT</b> .....	<i>Stereotactic body radiotherapy</i>
<b>SCC</b> .....	<i>Spinal cord compression</i>
<b>SDF-1</b> .....	<i>Stromal cell derived factor 1</i>

## *List of Abbreviations (cont...)*

<b>Abb.</b>	<b>Full term</b>
<b><i>SOAPP</i></b> .....	<i>Screeners and Opioid Assessment for Patients</i>
<b><i>SOAPP-R</i></b> .....	<i>Screeners and Opioid Assessment for Patients with Pain-Revised</i>
<b><i>SPEP</i></b> .....	<i>Serum protein electrophoresis</i>
<b><i>TC 99m</i></b> .....	<i>Technetium-99</i>
<b><i>UPEP</i></b> .....	<i>Urine protein electrophoresis</i>
<b><i>WHO</i></b> .....	<i>World Health Organization</i>

## INTRODUCTION

The most common cause of pain in cancer patients is bone metastases (*Coleman, 2006*). Among solid cancers, prostate, breast, thyroid, lung, and renal cell carcinoma account for 80 percent of all skeletal metastases (*Kvale et al., 2007*).

The primary disease site determines the prognosis for patients with bone metastases; patients with breast and prostate cancer have a longer median survival when it's compared with lung cancer (*Lutz et al., 2010*).

Bone metastases can be categorized as complicated or uncomplicated, where uncomplicated generally refers to the absence of: impending or established pathological fracture, previous surgical fixation, impending or established spinal cord compression, impending or established cauda equina or nerve root compression (including cranial nerves), neuropathic pain, previous radiation, or associated soft tissue mass. Approximately one-third of bone metastases are considered to be 'complicated' (*Tiwana et al., 2016*). Oligometastatic disease describes an intermediate state between disease that is localized to the primary site, and widespread metastases (*Weichselbaum et al., 2011*). The specific definition of oligometastases varies but in this review and as used by others, it means five or fewer metastatic lesions. Skeletal-related events typically encompass pathologic fracture, spinal cord compression, surgical

intervention or use of palliative radiotherapy (RT) (*Ibrahim et al., 2003*).

The treatment of an asymptomatic bone metastasis may be deferred unless the patient develops pain or is at risk for a skeletal-related event. The treatment of bone metastases may involve several types of systemic interventions, including chemotherapy, hormonal therapy, bisphosphonates, or radioisotopes, in addition to local interventions such as external beam radiotherapy (EBRT), stereotactic body radiotherapy (SBRT) hemi-body irradiation (HBI), radioisotopes, surgery, or percutaneous vertebral augmentation depending on the site and extent of disease, histology and biomarker profile of the metastasis (*Lutz et al., 2010*).

## **AIM OF THE WORK**

**T**he primary objective of the study is to determine whether short term radiation therapy (20 Gy of radiation therapy delivered in 5 treatment fractions) and long term radiation therapy (30 Gy of delivered in 10 treatment fractions) provide equivalent outcomes regarding pain for patients with painful bone metastases.